Molecular Partners (MOLN) Stock Forecast, Price Target & Predictions
MOLN Stock Forecast
Molecular Partners stock forecast is as follows: an average price target of $29.00 (represents a 378.55% upside from MOLN’s last price of $6.06) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
MOLN Price Target
The average price target for Molecular Partners (MOLN) is $29.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $29.00 to $29.00. This represents a potential 378.55% upside from MOLN's last price of $6.06.
MOLN Analyst Ratings
According to 2 Wall Street analysts, Molecular Partners's rating consensus is 'Buy'. The analyst rating breakdown for MOLN stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Molecular Partners Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 27, 2022 | - | Leerink Partners | $29.00 | $13.89 | 108.78% | 378.55% |
The latest Molecular Partners stock forecast, released on Apr 27, 2022 by Leerink Partners company, set a price target of $29.00, which represents a 108.78% increase from the stock price at the time of the forecast ($13.89), and a 378.55% increase from MOLN last price ($6.06).
Molecular Partners Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $6.06 | $6.06 | $6.06 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Molecular Partners stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Molecular Partners's last price of $6.06. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 27, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Apr 27, 2022 | Credit Suisse | - | Neutral | Downgrade |
Molecular Partners's last stock rating was published by SVB Leerink on Apr 27, 2022. The company gave MOLN a "Outperform" rating, the same as its previous rate.
Molecular Partners Financial Forecast
Molecular Partners Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $3.05M | $2.69M | $2.34M | $11.75M | $172.78M | $1.77M | $3.53M | $3.21M | $815.00K | $2.34M | $2.34M |
| Avg Forecast | $201.62K | $349.06K | $795.75K | $2.70M | $380.83K | $1.40M | $1.60M | $1.65M | $4.17M | $3.27M | $11.72M | $165.59M | $14.01M | $2.03M | $2.02M | $3.73M | $13.61M | $13.33M |
| High Forecast | $201.62K | $349.06K | $795.96K | $2.70M | $380.83K | $1.40M | $1.60M | $1.65M | $4.17M | $3.27M | $11.72M | $165.59M | $14.01M | $2.03M | $2.02M | $3.73M | $13.61M | $13.33M |
| Low Forecast | $201.62K | $349.06K | $795.53K | $2.70M | $380.83K | $1.40M | $1.60M | $1.65M | $4.17M | $3.27M | $11.72M | $165.59M | $14.01M | $2.03M | $2.02M | $3.73M | $13.61M | $13.33M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | 1.85% | 0.65% | 0.71% | 1.00% | 1.04% | 0.13% | 1.73% | 1.59% | 0.22% | 0.17% | 0.18% |
Molecular Partners's average Quarter revenue forecast for Jun 23 based on 1 analysts is $1.60M, with a low forecast of $1.60M, and a high forecast of $1.60M. MOLN's average Quarter revenue forecast represents a -47.45% decrease compared to the company's last Quarter revenue of $3.05M (Mar 23).
Molecular Partners EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | $-13.61M | $-13.72M | $-13.86M | $-5.56M | $153.26M | $-15.12M | $-12.18M | $-15.60M | $-17.86M | $-15.48M | $-15.48M |
| Avg Forecast | $-135.74K | $-235.01K | $-535.74K | $-1.82M | $-256.39K | $-939.95K | $-1.08M | $-1.11M | $-2.81M | $-2.20M | $-7.89M | $-111.48M | $-9.43M | $-1.37M | $-1.36M | $-2.51M | $-9.17M | $-8.98M |
| High Forecast | $-135.74K | $-235.01K | $-535.59K | $-1.82M | $-256.39K | $-939.95K | $-1.08M | $-1.11M | $-2.81M | $-2.20M | $-7.89M | $-111.48M | $-9.43M | $-1.37M | $-1.36M | $-2.51M | $-9.17M | $-8.98M |
| Low Forecast | $-135.74K | $-235.01K | $-535.88K | $-1.82M | $-256.39K | $-939.95K | $-1.08M | $-1.11M | $-2.81M | $-2.20M | $-7.89M | $-111.48M | $-9.43M | $-1.37M | $-1.36M | $-2.51M | $-9.17M | $-8.98M |
| Surprise % | - | - | - | - | - | - | - | 12.27% | 4.88% | 6.29% | 0.70% | -1.37% | 1.60% | 8.89% | 11.49% | 7.12% | 1.69% | 1.72% |
1 analysts predict MOLN's average Quarter EBITDA for Jun 22 to be $-7.89M, with a high of $-7.89M and a low of $-7.89M. This is -105.15% lower than Molecular Partners's previous annual EBITDA (Mar 22) of $153.26M.
Molecular Partners Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | $-15.32M | $-19.91M | $-11.95M | $-2.67M | $153.13M | $-17.91M | $-11.69M | $-17.63M | $-14.41M | $-15.69M | $-15.69M |
| Avg Forecast | $-12.66M | $-17.54M | $39.89M | $47.36M | $-28.70M | $42.22M | $35.44M | $43.40M | $-20.12M | $-21.44M | $-20.84M | $-20.14M | $-18.90M | $-18.56M | $-19.07M | $-24.74M | - | - |
| High Forecast | $-12.66M | $-17.54M | $39.89M | $47.36M | $-28.70M | $42.22M | $35.44M | $43.40M | $-20.12M | $-21.44M | $-20.84M | $-20.14M | $-18.90M | $-18.56M | $-19.07M | $-24.74M | - | - |
| Low Forecast | $-12.66M | $-17.54M | $39.89M | $47.36M | $-28.70M | $42.22M | $35.44M | $43.40M | $-20.12M | $-21.44M | $-20.84M | $-20.14M | $-18.90M | $-18.56M | $-19.07M | $-24.74M | - | - |
| Surprise % | - | - | - | - | - | - | - | -0.35% | 0.99% | 0.56% | 0.13% | -7.60% | 0.95% | 0.63% | 0.92% | 0.58% | - | - |
Molecular Partners's average Quarter net income forecast for Jun 22 is $-20.84M, with a range of $-20.84M to $-20.84M. MOLN's average Quarter net income forecast represents a -113.61% decrease compared to the company's last Quarter net income of $153.13M (Mar 22).
Molecular Partners SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | $5.44M | $5.03M | $5.56M | $5.48M | $5.76M | $4.59M | $4.69M | $4.29M | $3.34M | $2.77M | $2.77M |
| Avg Forecast | $260.16K | $450.43K | $1.03M | $3.48M | $491.42K | $1.80M | $2.07M | $2.13M | $5.39M | $4.22M | $15.12M | $213.67M | $18.08M | $2.62M | $2.60M | $4.81M | $17.57M | $17.20M |
| High Forecast | $260.16K | $450.43K | $1.03M | $3.48M | $491.42K | $1.80M | $2.07M | $2.13M | $5.39M | $4.22M | $15.12M | $213.67M | $18.08M | $2.62M | $2.60M | $4.81M | $17.57M | $17.20M |
| Low Forecast | $260.16K | $450.43K | $1.03M | $3.48M | $491.42K | $1.80M | $2.07M | $2.13M | $5.39M | $4.22M | $15.12M | $213.67M | $18.08M | $2.62M | $2.60M | $4.81M | $17.57M | $17.20M |
| Surprise % | - | - | - | - | - | - | - | 2.56% | 0.93% | 1.32% | 0.36% | 0.03% | 0.25% | 1.79% | 1.65% | 0.70% | 0.16% | 0.16% |
Molecular Partners's average Quarter SG&A projection for Jun 23 is $2.07M, based on 1 Wall Street analysts, with a range of $2.07M to $2.07M. The forecast indicates a -62.00% fall compared to MOLN last annual SG&A of $5.44M (Mar 23).
Molecular Partners EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | $-0.47 | $-0.61 | $-0.37 | $-0.08 | $4.74 | $-0.55 | $-0.36 | $-0.55 | $-0.49 | $-0.63 | $-0.63 |
| Avg Forecast | $-0.38 | $-0.53 | $1.20 | $1.43 | $-0.86 | $1.27 | $1.07 | $1.31 | $-0.61 | $-0.65 | $-0.63 | $-0.61 | $-0.57 | $-0.56 | $-0.57 | $-0.75 | - | - |
| High Forecast | $-0.38 | $-0.53 | $1.20 | $1.43 | $-0.86 | $1.27 | $1.07 | $1.31 | $-0.61 | $-0.65 | $-0.63 | $-0.61 | $-0.57 | $-0.56 | $-0.57 | $-0.75 | - | - |
| Low Forecast | $-0.38 | $-0.53 | $1.20 | $1.43 | $-0.86 | $1.27 | $1.07 | $1.31 | $-0.61 | $-0.65 | $-0.63 | $-0.61 | $-0.57 | $-0.56 | $-0.57 | $-0.75 | - | - |
| Surprise % | - | - | - | - | - | - | - | -0.36% | 1.01% | 0.57% | 0.13% | -7.81% | 0.97% | 0.64% | 0.96% | 0.66% | - | - |
According to 1 Wall Street analysts, Molecular Partners's projected average Quarter EPS for Jun 22 is $-0.63, with a low estimate of $-0.63 and a high estimate of $-0.63. This represents a -113.25% decrease compared to MOLN previous annual EPS of $4.74 (Mar 22).
Molecular Partners Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.64 | $24.75 | 1409.15% | Buy |
| ANTX | AN2 Therapeutics | $1.08 | $8.75 | 710.19% | Buy |
| MOLN | Molecular Partners | $6.06 | $29.00 | 378.55% | Buy |
| PEPG | PepGen | $6.79 | $29.50 | 334.46% | Buy |
| OPT | Opthea | $4.21 | $14.00 | 232.54% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.89 | $6.00 | 217.46% | Buy |
| VIGL | Vigil Neuroscience | $3.87 | $11.00 | 184.24% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| RZLT | Rezolute | $5.44 | $13.50 | 148.16% | Buy |
| MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
| PHVS | Pharvaris | $23.93 | $39.67 | 65.78% | Buy |
| EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
| TRDA | Entrada Therapeutics | $17.77 | $18.00 | 1.29% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
MOLN Forecast FAQ
Is Molecular Partners a good buy?
Yes, according to 2 Wall Street analysts, Molecular Partners (MOLN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of MOLN's total ratings.
What is MOLN's price target?
Molecular Partners (MOLN) average price target is $29 with a range of $29 to $29, implying a 378.55% from its last price of $6.06. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Molecular Partners stock go up soon?
According to Wall Street analysts' prediction for MOLN stock, the company can go up by 378.55% (from the last price of $6.06 to the average price target of $29), up by 378.55% based on the highest stock price target, and up by 378.55% based on the lowest stock price target.
Can Molecular Partners stock reach $9?
MOLN's average twelve months analyst stock price target of $29 supports the claim that Molecular Partners can reach $9 in the near future.
What are Molecular Partners's analysts' financial forecasts?
Molecular Partners's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $5.03M (high $5.03M, low $5.03M), average EBITDA is $-3.385M (high $-3.385M, low $-3.385M), average net income is $92.37M (high $92.37M, low $92.37M), average SG&A $6.49M (high $6.49M, low $6.49M), and average EPS is $2.78 (high $2.78, low $2.78). MOLN's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $4.05M (high $4.05M, low $4.05M), average EBITDA is $-2.724M (high $-2.724M, low $-2.724M), average net income is $57.05M (high $57.05M, low $57.05M), average SG&A $5.22M (high $5.22M, low $5.22M), and average EPS is $1.72 (high $1.72, low $1.72).
Did the MOLN's actual financial results beat the analysts' financial forecasts?
Based on Molecular Partners's last annual report (Dec 2022), the company's revenue was $189.56M, beating the average analysts forecast of $184.75M by 2.60%. Apple's EBITDA was $120.13M, missing the average prediction of $-124M by -196.58%. The company's net income was $117.85M, missing the average estimation of $-82.543M by -242.78%. Apple's SG&A was $21.82M, missing the average forecast of $238.4M by -90.85%. Lastly, the company's EPS was $3.63, missing the average prediction of $-2.488 by -245.93%. In terms of the last quarterly report (Mar 2023), Molecular Partners's revenue was $3.05M, beating the average analysts' forecast of $1.65M by 85.08%. The company's EBITDA was $-13.614M, beating the average prediction of $-1.109M by 1127.10%. Molecular Partners's net income was $-15.323M, missing the average estimation of $43.4M by -135.30%. The company's SG&A was $5.44M, beating the average forecast of $2.13M by 155.97%. Lastly, the company's EPS was $-0.47, missing the average prediction of $1.31 by -135.93%